TACE / Liver Ablation (RFA, MWA, Y-90)
Image-guided treatment of hepatocellular carcinoma and liver metastases. Transarterial chemoembolization (TACE) delivers chemotherapy-loaded beads into tumor-feeding hepatic arteries. Radiofrequency (RFA) and microwave ablation (MWA) thermally destroy tumors under CT or ultrasound guidance. Y-90 radioembolization delivers yttrium-90 microspheres transarterially for larger or more diffuse disease.
Clinical pathway
TACE: femoral access, selective hepatic arteriography, cone-beam CT to confirm tumor-feeding vessels, superselective microcatheter delivery of drug-eluting beads or lipiodol + doxorubicin, post-embolization angiogram.
RFA / MWA: CT- or ultrasound-guided percutaneous probe placement, ablation cycles per vendor protocol, post-ablation CT to confirm coverage and look for residual viable tumor.
Y-90: pre-treatment mapping angiogram + MAA SPECT scan for lung-shunt fraction, second visit for Y-90 delivery, post-delivery Bremsstrahlung SPECT or PET / CT distribution scan.
Typical systems
- Philips Azurion 7 (TACE + Y-90)
- Philips Allura Xper FD20 with XperCT
- Siemens Artis Q with DynaCT
- Siemens Artis zee with DynaCT
- GE Innova 2100-IQ
- CT for ablation guidance — SOMATOM Force, Revolution CT, Aquilion ONE
Room + procedure characteristics
- Procedure time: TACE 60–180 min, RFA / MWA 45–90 min per lesion, Y-90 30–60 min.
- Team: interventional radiologist + IR tech + RN; nuclear medicine tech for Y-90.
- Imaging: cone-beam CT on the IR system is near-mandatory for modern TACE.
Equipment considerations that bite
- CBCT / DynaCT / XperCT is the load-bearing feature for modern TACE. Soft-tissue 3D rotational CT plus tumor-feeder detection (EmboGuide, Embolization Planning) defines what TACE rooms can offer in 2025. A refurb angio room without CBCT licensing is a generation behind.
- Detector size — large-FOV / FD20-class is preferred for liver work. FD10 cardiac rooms are workable for small lesions but limit anatomic coverage.
- CT for ablation guidance — fluoroCT and CT-fluoro modes drive RFA / MWA procedure time. A diagnostic CT without fluoroCT licensing is much slower for ablation cases.
- Ablation generator inventory — Cool-tip, Emprint, NeuWave, AngioDynamics; vendor-specific probes and generators. Site stocking and reprocessing protocols matter.
- Y-90 hot lab + delivery — Sirtex SIR-Spheres and Boston Scientific TheraSphere have different administration kits; the IR room becomes a temporary hot-lab during delivery. NRC license amendments are program-defining events.
- Tube heat capacity — long TACE cases under high-mag cone-beam runs hit thermal limits on tired tubes.
Regulatory + safety reality
- Y-90 program — Authorized User physician (Part 35.300), NRC / Agreement-State license, dose calibrator daily QC, post-delivery survey, sealed-source accountability for Y-90 delivery system.
- Contrast volume management — TACE cases use significant iodinated contrast on patients commonly with marginal renal function; protocol pacing matters.
- Radiation safety in RFA / MWA — CT-fluoro protocols expose operator hands; lead-lined gloves, table draping, and dose-tracking for the operator are program-level disciplines.
Operational reality
- Multidisciplinary tumor board is the upstream demand driver — TACE / Y-90 / ablation case selection happens there, not in the IR clinic. Programs without active hepatobiliary tumor boards run lower-volume.
- Throughput is hot-lab + holding-bay, not the angio room. Y-90 program economics depend on case-stacking that the entire pre-/post-anesthesia chain can support.
- Refurb economics — angio rooms with CBCT licensing carry meaningful premium; rooms without it are either FD10 cardiac or older interventional configurations not well-suited to current liver-tumor practice.